title: Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
abstract: OBJECTIVE
  To report the long-term impact of two cycles of adjuvant chemotherapy on relapse rates and treatment-related morbidity in high-risk stage I nonseminomatous testicular germ cell tumors (NSGCTT I).
  
  
  METHODS
  From April 1987 to September 1997, 40 stage I NSGCTT patients with evidence of vascular invasion and/or embryonal carcinoma (EC) in the orchidectomy specimen were treated with two courses of bleomycin, cisplatin, and etoposide (BEP).
  
  
  RESULTS
  All patients but one (incidental death) were alive after an extended follow-up (median 113.2 months, range 63-189). No patients relapsed but two patients presented a second cancer in the remaining testis. Short-term toxicity was minimal and no long-term toxicity was observed.
  
  
  CONCLUSIONS
  The present series, with extensive follow-up, demonstrated that the efficacy and toxicity of two cycles of BEP compared well with the results of surveillance strategies or RPLND in high-risk stage I NSGCTT.
authors.affiliation: Department of Medical Oncology, Institut Claudius Regaud, 20, 24 rue du Pont Saint Pierre, 31052 Toulouse Cedex, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Chevreau
authors.forename: Catherine
authors.initials: C
authors.lastname: Mazerolles
authors.forename: Michel
authors.initials: M
authors.lastname: Soulié
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Gaspard
authors.forename: Loïc
authors.initials: L
authors.lastname: Mourey
authors.forename: Louis
authors.initials: L
authors.lastname: Bujan
authors.forename: Pierre
authors.initials: P
authors.lastname: Plante
authors.forename: Pascal
authors.initials: P
authors.lastname: Rischmann
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Bachaud
authors.forename: Bernard
authors.initials: B
authors.lastname: Malavaud
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage*; D018236:Carcinoma, Embryonal / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage*; D005047:Etoposide / Q000008:administration & dosage*; D005500:Follow-Up Studies; D018237:Germinoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D019043:Vascular Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin